New hope for NRAS-Mutant cancers: targeted drug binimetinib under study
NCT ID NCT04439344
First seen Nov 19, 2025 · Last updated Jun 23, 2026 · Updated 22 times
Summary
This phase II trial is testing the drug binimetinib in 53 people whose cancers (excluding melanoma) have a specific genetic change called an NRAS mutation. Binimetinib blocks certain proteins that help these cancer cells grow. The study aims to see if the drug can shrink tumors or stop them from growing. It is part of the larger MATCH program, which matches treatments to genetic changes in a patient's tumor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Binimetinib (a drug that blocks MEK proteins, which cancer cells with NRAS mutations may need to grow)
What this could lead to
If it works, this could provide a treatment option for several types of cancer that share an NRAS mutation, especially when other treatments have failed.
What could go wrong
This is a small, early-phase trial (53 people) across many cancer types, so results may not apply broadly. The drug may not shrink tumors or improve survival, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.